Welcome to Scientelle

Scientelle is a US-based life science corporation developing a family of novel anti-infective non-antibiotic products for treatment and prevention of Bacterial Vaginosis with further potential in prevention of preterm birth.

In our development strategy we are focusing on creating value through fast transition from pre-clinical to clinical development and efficient execution of phase I-II programs. This approach is grounded in strength of our IP, unique expertize of our team in development and commercialization of vaginal pharmaceutical applications, established relationships with leading academic groups and research organizations in Eastern Europe, as well as productive collaboration with leading scientific experts in the US.

In 2013 we successfully completed a robust in-vitro proof-of-concept program, which clearly demonstrated that SCI-221, our non-antibiotic product for treatment and prevention of Bacterial Vaginosis has a required selectivity and kinetics of antibacterial effect. Now we are rapidly moving into the clinical phase and are seeking investment to support the expedited completion of clinical proof-of-concept.